# Implications for Management of PET Amyloid Classification Technology

> **NCT02778971** · — · COMPLETED · sponsor: **University of Utah** · enrollment: 41 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Dementia
- Alzheimer's Disease

## Interventions

- **DRUG:** [18F]Flutemetamol

## Key facts

- **NCT ID:** NCT02778971
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2018-06
- **Final completion:** 2022-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02778971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02778971, "Implications for Management of PET Amyloid Classification Technology". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02778971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*